On Thursday, April 14, 2022, the Food and Drug Authority (FDA) issued the first device that determines infection with the emerging coronavirus by taking breath samples.
The size of the carry-on baggage size of the InspectIR COVID-19 Breathalyzer, the FDA has stated, it can be used in clinics, hospitals, and can also be used at mobile medical test sites. The examination that provides immediate results for a period of no more than 3 minutes is required to be supervised by an authorized person from the official health care institutions.
The FDA confirmed that the device can detect negative samples with an accuracy of 99.3% and positive samples with an accuracy of 91.2%.
InspectIR is expected to produce approximately 100 devices in one week, with up to 160 samples analyzed per day.
Source:
English (UK) 
العربية